BRCA1-mediated signaling pathways in ovarian carcinogenesis

Functional and Integrative Genomics

Volumn 12, Issue 1, 2012, Pages 63-79

  Karve, Tejaswita M ^a   Li, Xin ^a   Saha, Tapas ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

c Myc; Hierarchical clustering; Ingenuity pathway analysis; NF B; p53; TNF

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL COMMUNICATION; CELL CYCLE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DNA MODIFICATION; DNA REPLICATION; FEMALE; GENE; GENE CLUSTER; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC STABILITY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MICROARRAY ANALYSIS; NUCLEAR FACTOR KAPPA B GENE; ONCOGENE C MYC; OVARY CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECOMBINATION REPAIR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TGF BETA1 GENE; TP53 GENE; TUMOR NECROSIS FACTOR ALPHA GENE; TUMOR SUPPRESSOR GENE;

BRCA1 PROTEIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; DNA REPAIR; DNA REPLICATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROTEIN INTERACTION MAPS; SIGNAL TRANSDUCTION;

EID: 84858439409     PISSN: 1438793X     EISSN: 14387948     Source Type: Journal    
DOI: 10.1007/s10142-011-0251-2     Document Type: Article

References (73)

1. AA Ahmed D Etemadmoghadam J Temple AG Lynch M Riad R Sharma C Stewart S Fereday C Caldas A Defazio D Bowtell JD Brenton 2010 Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary J Pathol 221 1 49 56 10.1002/path.2696 20229506 10.1002/path.2696 1:CAS:528:DC%2BC3cXntFyjsL4%3D
2. R Ali-Fehmi M Chatterjee A Ionan NK Levin H Arabi S Bandyopadhyay JP Shah CS Bryant SM Hewitt MG O'Rand OM Alekseev R Morris A Munkarah J Abrams MA Tainsky 2010 Analysis of the expression of human tumor antigens in ovarian cancer tissues Cancer Biomark 6 1 33 48 10.3233/CBM-2009-0117 20164540
3. J Aravindakshan X Chen MR Sairam 2006 Differential expression of claudin family proteins in mouse ovarian serous papillary epithelial adenoma in aging FSH receptor-deficient mutants Neoplasia 8 12 984 994 10.1593/neo.06529 17217615 10.1593/neo.06529 1:CAS:528:DC%2BD2sXjsVGjtA%3D%3D (Pubitemid 44936148)
4. I Bae JK Rih HJ Kim HJ Kang B Haddad A Kirilyuk S Fan ML Avantaggiati EM Rosen 2005 BRCA1 regulates gene expression for orderly mitotic progression Cell Cycle 4 11 1641 1666 16258266 10.4161/cc.4.11.2152 1:CAS:528: DC%2BD28XktVCgtr0%3D
5. S Banerjee SB Kaye A Ashworth 2010 Making the best of PARP inhibitors in ovarian cancer Nat Rev Clin Oncol 7 9 508 519 10.1038/nrclinonc.2010.116 20700108 10.1038/nrclinonc.2010.116 1:CAS:528:DC%2BC3cXhtVyjsr%2FM
6. L Bjorge H Stoiber MP Dierich S Meri 2006 Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy Scand J Immunol 63 5 355 364 10.1111/j.1365-3083.2006.01751.x 16640659 10.1111/j.1365-3083.2006.01751.x 1:STN:280:DC%2BD283jsFamtg%3D%3D
7. T Bonome JY Lee DC Park M Radonovich C Pise-Masison J Brady GJ Gardner K Hao WH Wong JC Barrett KH Lu AK Sood DM Gershenson SC Mok MJ Birrer 2005 Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary Cancer Res 65 22 10602 10612 10.1158/0008-5472. CAN-05-2240 16288054 10.1158/0008-5472.CAN-05-2240 1:CAS:528:DC%2BD2MXht1Wgu73M (Pubitemid 41743756)
8. JM Bronstein S Tiwari-Woodruff AG Buznikov DB Stevens 2000 Involvement of OSP/claudin-11 in oligodendrocyte membrane interactions: role in biology and disease J Neurosci Res 59 6 706 711 10.1002/(SICI)1097-4547(20000315)59: 6<706::AID-JNR2>3.0.CO;2-D 10700007 10.1002/(SICI)1097-4547(20000315)59: 6<706::AID-JNR2>3.0.CO;2-D 1:CAS:528:DC%2BD3cXhvValt74%3D
9. G Castellano JF Reid P Alberti ML Carcangiu A Tomassetti S Canevari 2006 New potential ligand-receptor signaling loops in ovarian cancer identified in multiple gene expression studies Cancer Res 66 22 10709 10719 10.1158/0008-5472.CAN-06-1327 17090524 10.1158/0008-5472.CAN-06-1327 1:CAS:528:DC%2BD2sXivVyqsL4%3D (Pubitemid 44876966)
10. CH Chen J Shen WJ Lee SN Chow 2005 Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer Int J Gynecol Cancer 15 5 878 883 10.1111/j.1525-1438.2005.00150.x 16174239 10.1111/j.1525-1438.2005. 00150.x (Pubitemid 41783096)
11. KV Clark-Knowles AM O'Brien JI Weberpals 2010 BRCA1 as a therapeutic target in sporadic epithelial ovarian cancer J Oncol 2010 891059 10.1155/2010/891059 20182637
12. RT Dorsam JS Gutkind 2007 G-protein-coupled receptors and cancer Nat Rev Cancer 7 2 79 94 10.1038/nrc2069 17251915 10.1038/nrc2069 1:CAS:528: DC%2BD2sXotFOisw%3D%3D (Pubitemid 46164746)
13. S Fan JA Wang RQ Yuan YX Ma Q Meng MR Erdos LC Brody ID Goldberg EM Rosen 1998 BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins Oncogene 16 23 3069 3082 9662340 10.1038/sj.onc.1202116 1:CAS:528: DyaK1cXktFejs7c%3D (Pubitemid 28297729)
14. JP Geisler MA Hatterman-Zogg JA Rathe RE Buller 2002 Frequency of BRCA1 dysfunction in ovarian cancer J Natl Cancer Inst 94 1 61 67 11773283 10.1093/jnci/94.1.61 1:CAS:528:DC%2BD38Xit1amtL8%3D (Pubitemid 34082844)
15. A Giudice M Montella 2006 Activation of the Nrf2-ARE signaling pathway: a promising strategy in cancer prevention Bioessays 28 2 169 181 10.1002/bies.20359 16435293 10.1002/bies.20359 1:CAS:528:DC%2BD28XitVCkt7w%3D
16. S Glaros GM Cirrincione C Muchardt CG Kleer CW Michael D Reisman 2007 The reversible epigenetic silencing of BRM: implications for clinical targeted therapy Oncogene 26 49 7058 7066 10.1038/sj.onc.1210514 17546055 10.1038/sj.onc.1210514 1:CAS:528:DC%2BD2sXht1Wgt7rN (Pubitemid 350014614)
17. LJ Havrilesky CP McMahon EK Lobenhofer R Whitaker JR Marks A Berchuck 2001 Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones J Soc Gynecol Investig 8 2 104 113 11336882 10.1016/S1071-5576(01) 00093-4 1:CAS:528:DC%2BD3MXjtFGgsrc%3D (Pubitemid 32385404)
18. J He ER Smith XX Xu 2001 Disabled-2 exerts its tumor suppressor activity by uncoupling c-Fos expression and MAP kinase activation J Biol Chem 276 29 26814 26818 10.1074/jbc.M101820200 11359772 10.1074/jbc.M101820200 1:CAS:528:DC%2BD3MXlsV2jsbo%3D
19. CH Holschneider JS Berek 2000 Ovarian cancer: epidemiology, biology, and prognostic factors Semin Surg Oncol 19 1 3 10 10.1002/1098-2388(200007/08)19: 1<3::AID-SSU2>3.0.CO;2-S 10883018 10.1002/1098-2388(200007/08)19:1<3:: AID-SSU2>3.0.CO;2-S 1:STN:280:DC%2BD3cvgslehsg%3D%3D (Pubitemid 30439309)
20. Y Hoshiya V Gupta DL Segev M Hoshiya JL Carey LM Sasur TT Tran TU Ha S Maheswaran 2003 Mullerian Inhibiting Substance induces NFkB signaling in breast and prostate cancer cells Mol Cell Endocrinol 211 1-2 43 49 14656475 10.1016/j.mce.2003.09.010 1:CAS:528:DC%2BD3sXptlOrsLg%3D (Pubitemid 37491234)
21. Y Jiang M Berk LS Singh H Tan L Yin CT Powell Y Xu 2005 KiSS1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase C alpha Clin Exp Metastasis 22 5 369 376 10.1007/s10585-005-8186-4 16283480 10.1007/s10585-005-8186-4 1:CAS:528:DC%2BD28Xit1KlsQ%3D%3D (Pubitemid 41609296)
22. T Jiang S Wang L Huang S Zhang 2009 Clinical significance of serum DKK-1 in patients with gynecological cancer Int J Gynecol Cancer 19 7 1177 1181 10.1111/IGC.0b013e31819d8b2d 19820386 10.1111/IGC.0b013e31819d8b2d
23. T Jiang L Huang S Wang S Zhang 2010 Clinical significance of serum Dkk-3 in patients with gynecological cancer J Obstet Gynaecol Res 36 4 769 773 10.1111/j.1447-0756.2010.01234.x 20666943 10.1111/j.1447-0756.2010.01234.x 1:CAS:528:DC%2BC3cXhtFOnsrbE
24. CN Johnstone S Castellvi-Bel LM Chang RK Sung MJ Bowser JM Pique A Castells AK Rustgi 2005 PRR5 encodes a conserved proline-rich protein predominant in kidney: analysis of genomic organization, expression, and mutation status in breast and colorectal carcinomas Genomics 85 3 338 351 10.1016/j.ygeno.2004.11.002 15718101 10.1016/j.ygeno.2004.11.002 1:CAS:528:DC%2BD2MXhsVGns70%3D (Pubitemid 40249426)
25. W Ju BC Yoo IJ Kim JW Kim SC Kim HP Lee 2009 Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays Oncol Res 18 2-3 47 56 20066894 10.3727/096504009789954672 1:CAS:528:DC%2BC3cXisVejsw%3D%3D
26. GM Kasof JJ Lu D Liu B Speer KN Mongan BC Gomes MV Lorenzi 2001 Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB Oncogene 20 55 7965 7975 10.1038/sj.onc.1204985 11753679 10.1038/sj.onc.1204985 1:CAS:528: DC%2BD3MXptlKrsrw%3D (Pubitemid 34001557)
27. M Katoh 2007 Conserved POU/OCT- and GATA-binding sites in 5′-flanking promoter region of mammalian WNT8B orthologs Int J Oncol 30 5 1273 1277 17390031 1:CAS:528:DC%2BD2sXlsVCmsLo%3D
28. SM Keyse 2008 Dual-specificity MAP kinase phosphatases (MKPs) and cancer Cancer Metastasis Rev 27 2 253 261 10.1007/s10555-008-9123-1 18330678 10.1007/s10555-008-9123-1 1:CAS:528:DC%2BD1cXlt1Ckurg%3D
29. YS Kim JD Hwan S Bae DH Bae WA Shick 2010 Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma BMC Cancer 10 576 10.1186/1471-2407-10-576 20969748 10.1186/1471-2407-10-576 1:CAS:528:DC%2BC3cXhtl2kurbL
30. L Kleinberg A Holth E Fridman I Schwartz M Shih Ie B Davidson 2007 The diagnostic role of claudins in serous effusions Am J Clin Pathol 127 6 928 937 10.1309/V025QRN3R9CJGNPX 17509990 10.1309/V025QRN3R9CJGNPX 1:CAS:528: DC%2BD2sXntVCntbg%3D
31. HB Koon GC Ippolito AH Banham PW Tucker 2007 FOXP1: a potential therapeutic target in cancer Expert Opin Ther Targets 11 7 955 965 10.1517/14728222.11.7.955 17614763 10.1517/14728222.11.7.955 1:CAS:528:DC%2BD2sXnt1Kgtrs%3D (Pubitemid 47061317)
32. C Le Page ML Puiffe L Meunier M Zietarska M de Ladurantaye PN Tonin D Provencher AM Mes-Masson 2009 BMP-2 signaling in ovarian cancer and its association with poor prognosis J Ovarian Res 2 4 10.1186/1757-2215-2-4 19366455 10.1186/1757-2215-2-4
33. SW Lee CL Reimer L Fang ML Iruela-Arispe SA Aaronson 2000 Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression Mol Cell Biol 20 5 1723 1732 10669749 10.1128/MCB.20.5.1723-1732.2000 1:CAS:528:DC%2BD3cXhtF2nt7c%3D (Pubitemid 30100191)
34. J Li WH Wood 3rd KG Becker AT Weeraratna PJ Morin 2007 Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells Oncogene 26 20 2860 2872 10.1038/sj.onc.1210086 17072341 10.1038/sj.onc.1210086 1:CAS:528:DC%2BD2sXkvVansLs%3D (Pubitemid 46701436)
35. CJ Lord A Ashworth 2008 Targeted therapy for cancer using PARP inhibitors Curr Opin Pharmacol 8 4 363 369 10.1016/j.coph.2008.06.016 18644251 10.1016/j.coph.2008.06.016 1:CAS:528:DC%2BD1cXhtFCktL7I
36. A Mahajan Z Liu L Gellert X Zou G Yang P Lee X Yang JJ Wei 2010 HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma Mod Pathol 23 5 673 681 10.1038/modpathol.2010.49 20228781 10.1038/modpathol.2010. 49 1:CAS:528:DC%2BC3cXlsFSjtrw%3D
37. S Malki F Bibeau C Notarnicola S Roques P Berta F Poulat B Boizet-Bonhoure 2007 Expression and biological role of the prostaglandin D synthase/SOX9 pathway in human ovarian cancer cells Cancer Lett 255 2 182 193 10.1016/j.canlet.2007.04.007 17532558 10.1016/j.canlet.2007.04.007 1:CAS:528:DC%2BD2sXpsFKqurY%3D (Pubitemid 47268638)
38. F Mancini F Moretti 2009 Mitochondrial MDM4 (MDMX): an unpredicted role in the p53-mediated intrinsic apoptotic pathway Cell Cycle 8 23 3854 3859 19887911 10.4161/cc.8.23.10089 1:CAS:528:DC%2BC3cXotlWrtL0%3D
39. J Massague D Wotton 2000 Transcriptional control by the TGF-beta/Smad signaling system EMBO J 19 8 1745 1754 10.1093/emboj/19.8.1745 10775259 10.1093/emboj/19.8.1745 1:CAS:528:DC%2BD3cXivVKlsbo%3D (Pubitemid 30204386)
40. K Milde-Langosch M Hagen AM Bamberger T Loning 2003 Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer Int J Gynecol Pathol 22 2 168 174 12649672 10.1097/00004347-200304000-00009 (Pubitemid 36348791)
41. G Moreno-Bueno S Rodriguez-Perales C Sanchez-Estevez D Hardisson D Sarrio J Prat JC Cigudosa X Matias-Guiu J Palacios 2003 Cyclin D1 gene (CCND1) mutations in endometrial cancer Oncogene 22 38 6115 6118 10.1038/sj.onc.1206868 12955092 10.1038/sj.onc.1206868 1:CAS:528:DC%2BD3sXmvFansb0%3D (Pubitemid 37175891)
42. MM Murph W Liu S Yu Y Lu H Hall BT Hennessy J Lahad M Schaner A Helland G Kristensen AL Borresen-Dale GB Mills 2009 Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis PLoS One 4 5 e5583 10.1371/journal.pone.0005583 19440550 10.1371/journal.pone.0005583
43. National Cancer Institute (2010) Cancer Trends Progress Report 2009/2010 Update
44. E Ntougkos R Rush D Scott T Frankenberg H Gabra JF Smyth GC Sellar 2005 The IgLON family in epithelial ovarian cancer: expression profiles and clinicopathologic correlates Clin Cancer Res 11 16 5764 5768 10.1158/1078-0432.CCR-04-2388 16115914 10.1158/1078-0432.CCR-04-2388 1:CAS:528:DC%2BD2MXos1Cjtrs%3D (Pubitemid 41170301)
45. N Petrucelli MB Daly GL Feldman 2010 Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2 Genet Med 12 5 245 259 10.1097/GIM. 0b013e3181d38f2f 20216074 10.1097/GIM.0b013e3181d38f2f 1:CAS:528: DC%2BC3cXlvVenu74%3D
46. KL Pierce RT Premont RJ Lefkowitz 2002 Seven-transmembrane receptors Nat Rev Mol Cell Biol 3 9 639 650 10.1038/nrm908 12209124 10.1038/nrm908 1:CAS:528:DC%2BD38Xmslansr4%3D (Pubitemid 34987785)
47. P Polakis 1999 The oncogenic activation of beta-catenin Curr Opin Genet Dev 9 1 15 21 S0959-437X(99)80003-3 10072352 10.1016/S0959-437X(99)80003-3 1:CAS:528:DyaK1MXhsFSnt7Y%3D (Pubitemid 29080382)
48. R Rattan K Narita J Chien JL Maguire R Shridhar S Giri V Shridhar 2010 TCEAL7, a putative tumor suppressor gene, negatively regulates NF-kappaB pathway Oncogene 29 9 1362 1373 10.1038/onc.2009.431 19966855 10.1038/onc.2009.431 1:CAS:528:DC%2BD1MXhsFWrsbnE
49. MH Roh Y Yassin A Miron KK Mehra M Mehrad NM Monte GL Mutter MR Nucci G Ning FD McKeon MS Hirsch X Wa CP Crum 2010 High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression Mod Pathol 23 10 1316 1324 10.1038/modpathol.2010.119 20562848 10.1038/modpathol.2010.119 1:CAS:528:DC%2BC3cXht1emtb7I
50. EM Rosen S Fan Y Ma 2006 BRCA1 regulation of transcription Cancer Lett 236 2 175 185 10.1016/j.canlet.2005.04.037 15975711 10.1016/j.canlet.2005.04.037 1:CAS:528:DC%2BD28XkvVynu74%3D
51. T Saha JK Rih R Roy R Ballal EM Rosen 2010 Transcriptional regulation of the base excision repair pathway by BRCA1 J Biol Chem 2010 25
52. I Sekiya K Tsuji P Koopman H Watanabe Y Yamada K Shinomiya A Nifuji M Noda 2000 SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6 J Biol Chem 275 15 10738 10744 10753864 10.1074/jbc.275.15.10738 1:CAS:528: DC%2BD3cXislShsrw%3D (Pubitemid 30212701)
53. Z Sheng J He JA Tuppen W Sun Z Fazili ER Smith FB Dong XX Xu 2000 Structure, sequence, and promoter analysis of human disabled-2 gene (DAB2) Genomics 70 3 381 386 10.1006/geno.2000.6383 11161789 10.1006/geno.2000.6383 1:CAS:528:DC%2BD3MXjt1OrtQ%3D%3D (Pubitemid 32095437)
54. P Sicinski JL Donaher Y Geng SB Parker H Gardner MY Park RL Robker JS Richards LK McGinnis JD Biggers JJ Eppig RT Bronson SJ Elledge RA Weinberg 1996 Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis Nature 384 6608 470 474 10.1038/384470a0 8945475 10.1038/384470a0 1:CAS:528:DyaK28XnsFWqurc%3D (Pubitemid 26414665)
55. A Skrtic P Korac DR Kristo R Ajdukovic Stojisavljevic D Ivankovic M Dominis 2010 Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance Hum Pathol 41 12 1702 1710 10.1016/j.humpath.2010.05.002 20800871 10.1016/j.humpath.2010.05.002 1:CAS:528:DC%2BC3cXhsVWrur%2FN
56. H Surawska PC Ma R Salgia 2004 The role of ephrins and Eph receptors in cancer Cytokine Growth Factor Rev 15 6 419 433 10.1016/j.cytogfr.2004.09.002 15561600 10.1016/j.cytogfr.2004.09.002 1:CAS:528:DC%2BD2cXhtVSlurbM (Pubitemid 39550453)
57. I Szabo A Kiss Z Schaff G Sobel 2009 Claudins as diagnostic and prognostic markers in gynecological cancer Histol Histopathol 24 12 1607 1615 19795358 1:CAS:528:DC%2BD1MXhsVCktbbK
58. H Tashiro K Miyazaki H Okamura A Iwai M Fukumoto 1992 c-myc over-expression in human primary ovarian tumours: its relevance to tumour progression Int J Cancer 50 5 828 833 1544716 10.1002/ijc.2910500528 1:STN:280:DyaK387osVequg%3D%3D
59. A Tinelli A Malvasi G Leo D Vergara M Pisano M Ciccarese VE Chiuri V Lorusso 2010 Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal Cancer Metastasis Rev 29 2 339 350 10.1007/s10555-010-9218-3 20405170 10.1007/s10555-010-9218-3 1:CAS:528:DC%2BC3cXlslWgtrs%3D
60. SY Tong KD Ki JM Lee MJ Kang TK Ha SI Chung SG Chi SK Lee 2010 Frequent inactivation of hSRBC in ovarian cancers by promoter CpG island hypermethylation Acta Obstet Gynecol Scand 89 5 629 635 10.3109/00016341003678443 20423276 10.3109/00016341003678443 1:CAS:528:DC%2BC3cXlt1Crur8%3D
61. R Tummala D Wolle SP Barwe VB Sampson AK Rajasekaran L Pendyala 2009 Expression of Na, K-ATPase-beta(1) subunit increases uptake and sensitizes carcinoma cells to oxaliplatin Cancer Chemother Pharmacol 64 6 1187 1194 10.1007/s00280-009-0985-x 19322565 10.1007/s00280-009-0985-x 1:CAS:528:DC%2BD1MXhtVWhsrrE
62. D Wang T Kanuma H Mizumuma Y Ibuki S Takenoshita 2000 Mutation analysis of the Smad6 and Smad7 gene in human ovarian cancers Int J Oncol 17 6 1087 1091 11078792 1:CAS:528:DC%2BD3cXos1OntLc%3D
63. H Wang NC McKnight T Zhang ML Lu SP Balk X Yuan 2007 SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells Cancer Res 67 2 528 536 10.1158/0008-5472.CAN-06-1672 17234760 10.1158/0008-5472.CAN-06-1672 1:CAS:528:DC%2BD2sXmtVKltA%3D%3D (Pubitemid 46192189)
64. W Weichert V Gekeler C Denkert M Dietel S Hauptmann 2003 Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis Int J Oncol 23 3 633 639 12888898 1:CAS:528:DC%2BD3sXntVCjsLk%3D
65. SY Woo DH Kim CB Jun YM Kim EV Haar SI Lee JW Hegg S Bandhakavi TJ Griffin 2007 PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling J Biol Chem 282 35 25604 25612 10.1074/jbc.M704343200 17599906 10.1074/jbc.M704343200 1:CAS:528:DC%2BD2sXpsFWlt7s%3D (Pubitemid 47372842)
66. EM Wright B Snopek P Koopman 1993 Seven new members of the Sox gene family expressed during mouse development Nucleic Acids Res 21 3 744 8441686 10.1093/nar/21.3.744 1:CAS:528:DyaK3sXktVaisLY%3D (Pubitemid 23155572)
67. J Wu Z Liu C Shao Y Gong E Hernando P Lee M Narita W Muller J Liu JJ Wei 2011 HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes Cancer Res 71 2 349 359 10.1158/0008-5472.CAN-10-2550 21224353 10.1158/0008-5472.CAN-10-2550 1:CAS:528:DC%2BC3MXlsFKnug%3D%3D
68. JD Wulfkuhle JA Aquino VS Calvert DA Fishman G Coukos LA Liotta EF Petricoin 3rd 2003 Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays Proteomics 3 11 2085 2090 10.1002/pmic.200300591 14595806 10.1002/pmic.200300591 1:CAS:528: DC%2BD3sXptFKqtL8%3D (Pubitemid 37414073)
69. J Wynendaele A Bohnke E Leucci SJ Nielsen I Lambertz S Hammer N Sbrzesny D Kubitza A Wolf E Gradhand K Balschun I Braicu J Sehouli S Darb-Esfahani C Denkert C Thomssen S Hauptmann A Lund JC Marine F Bartel 2010 An illegitimate microRNA target site within the 3′ UTR of MDM4 affects ovarian cancer progression and chemosensitivity Cancer Res 70 23 9641 9649 10.1158/0008-5472. CAN-10-0527 21084273 10.1158/0008-5472.CAN-10-0527 1:CAS:528:DC%2BC3cXhsFamurrM
70. DH Yang Z Fazili ER Smith KQ Cai A Klein-Szanto C Cohen IR Horowitz XX Xu 2006 Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background Am J Pathol 169 1 258 267 10.2353/ajpath.2006.060036 16816378 10.2353/ajpath.2006.060036 1:CAS:528:DC%2BD28XnslSntb8%3D
71. A You E Fokas LF Wang H He B Kleb D Niederacher R Engenhart-Cabillic HX An 2011 Expression of the Wnt antagonist DKK3 is frequently suppressed in sporadic epithelial ovarian cancer J Cancer Res Clin Oncol 137 4 621 627 10.1007/s00432-010-0916-6 20532910 10.1007/s00432-010-0916-6 1:CAS:528:DC%2BC3MXjtV2lurk%3D
72. G Zabouo AM Imbert J Jacquemier P Finetti T Moreau B Esterni D Birnbaum F Bertucci C Chabannon 2009 CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines Breast Cancer Res 11 1 R1 10.1186/bcr2215 19123925 10.1186/bcr2215
73. Y Zhang A Scoumanne X Chen 2010 G protein-coupled receptor 87: a promising opportunity for cancer drug discovery Mol Cell Pharmacol 2 3 111 116 20686680 1:CAS:528:DC%2BC3cXovFGlur8%3D